# Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

> **NCT00678106** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT00678106
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2009-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678106, "Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00678106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*